Article
Immunology
Adri Chakraborty, Raghavendra Upadhya, Timaj A. Usman, Ashok K. Shetty, Joseph M. Rutkowski
Summary: The study investigated the impact of chronic VEGFR-3 signaling on adipose neuro-connections and neuroprotection in neurons both in vivo and in vitro. Results showed that chronic VEGFR-3 activation in adipose tissue decreased dendrite length, terminal branches, and volume, but increased dendrite branching. Furthermore, VEGFR-3 signaling provided neuroprotection in challenged neurons and improved dendritic arbor complexity, suggesting a synergistic impact on neurosensitization and neuroprotection during stress.
BRAIN BEHAVIOR AND IMMUNITY
(2021)
Article
Pharmacology & Pharmacy
Chenyang Shi, Jiaxin Li, Guorong Fan, Yu Liu
Summary: This study proposes a synergistic antitumour strategy by simultaneously blocking VEGF and CD47 signalling to enhance the therapeutic effect of bevacizumab on advanced gastric cancer. The results demonstrate that this strategy can reverse immune-related resistance, enhance antitumour effects, and inhibit tumour metastasis.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, Research & Experimental
Dhanashri Deshmukh, Ya Fen Hsu, Chien-Chih Chiu, Mahendra Jadhao, Sodio C. N. Hsu, Shao-Yang Hu, Shu-Hui Yang, Wangta Liu
Summary: This study evaluated the antiangiogenic effects of Lepista nuda water extract on zebrafish development and in vitro human umbilical vein endothelial cell (HUVEC) tube formation. Bioactive components such as ergothioneine, eritadenine, and adenosine were identified and quantified. The results suggest that L. nuda could be a potential inhibitor of angiogenesis limiting cancer progression.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Biochemistry & Molecular Biology
Peace Mabeta, Vanessa Steenkamp
Summary: The VEGF/VEGFR axis plays a crucial role in angiogenesis and tumor vascularization. Current therapies targeting VEGF and its receptors have shown limited effectiveness and undesirable off-target effects. Recent studies have identified VEGF splice variants that modulate angiogenesis, and their expression is regulated by cues within the tumor microenvironment. These variants challenge the established norm of VEGF signaling and their aberrant expression has been observed in several cancers, highlighting the need for further research on their role in cancer and their impact on antiangiogenic therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Chemistry, Medicinal
Die Jiang, Ting Xu, Lei Zhong, Qi Liang, Yonghe Hu, Wenjing Xiao, Jianyou Shi
Summary: Angiogenesis is a vital biological process for body growth and development, wound healing, and tissue formation. Dysregulation of VEGFR signaling can lead to diseases, making it a crucial research area for disease treatment. Currently, anti-VEGF drugs used in ophthalmology have limitations, and there is a need to develop small molecule inhibitors of VEGFR for the targeted treatment of ocular neovascularization diseases.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Mingxia Song, Jiantao Wen, Yi Hua, Yangnv Zhu, Qishan Xia, Qiaoyue Guo, Yiqin Luo, Xianqing Deng, Yushan Huang
Summary: Fourteen celastrol derivatives (1-14) were synthesized by esterifying celastrol at the 29th position. The MTT assay showed that all the synthetic compounds exhibited significant antiproliferative activity against six cancer cells at submicron molar levels. Compound 2, the most promising derivative, arrested the cell cycle in the G2 phase and suppressed the expression of VEGF and MMP-9 in gastric cancer cells. It also induced dose-dependent apoptosis in cancer cells and demonstrated significant in vivo anti-tumor activity in a mouse tumor xenograft model.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
(2023)
Review
Pharmacology & Pharmacy
Ivan Guryanov, Tatiana Tennikova, Arto Urtti
Summary: VEGFs play crucial roles in angiogenesis, but dysregulation can lead to pathological angiogenesis in various diseases. Monoclonal antibodies and decoy receptors are commonly used to neutralize VEGFA in anti-angiogenic therapies. Short peptides are promising alternatives to full-length VEGFA inhibitors, overcoming some limitations of existing therapies.
Article
Oncology
Catarina Nascimento, Andreia Gameiro, Joao Ferreira, Jorge Correia, Fernando Ferreira
Summary: Feline mammary carcinoma is the third most common neoplasia in cats, with highly malignant behavior. The study suggests that VEGF-A and its serum receptors assessment may have potential in the diagnosis and treatment of feline mammary carcinoma.
Article
Oncology
Laura Micheli, Carmen Parisio, Elena Lucarini, Alessia Vona, Alessandra Toti, Alessandra Pacini, Tommaso Mello, Serena Boccella, Flavia Ricciardi, Sabatino Maione, Grazia Graziani, Pedro Miguel Lacal, Paola Failli, Carla Ghelardini, Lorenzo Di Cesare Mannelli
Summary: Studies in murine models suggest that VEGF-A and its receptor VEGFR-1 play a crucial role in chemotherapy-induced neuropathic pain, mediating pain transmission through communication between astrocytes and neurons. Blocking VEGFR-1 may help alleviate neuropathic pain by disrupting this interaction.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Vinochani Pillay, Lipi Shukla, Prad Herle, Simon Maciburko, Nadeeka Bandara, Isabella Reid, Steven Morgan, Yinan Yuan, Jennii Luu, Karla J. Cowley, Susanne Ramm, Kaylene J. Simpson, Marc G. Achen, Steven A. Stacker, Ramin Shayan, Tara Karnezis
Summary: Surgery and radiotherapy are major cancer treatments that can cause damage to the lymphatic system, leading to lymphoedema. However, the molecular mechanisms underlying this damage to lymphatic vessels and endothelial cells remain poorly understood.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Maria Grazia Atzori, Claudia Ceci, Federica Ruffini, Manuel Scimeca, Rosella Cicconi, Maurizio Mattei, Pedro Miguel Lacal, Grazia Graziani
Summary: The study indicates that inhibiting the activation of VEGFR-1 by PlGF can effectively restrain the metastatic potential of melanoma, reducing tumor invasiveness and tropism toward bone tissue.
Article
Biochemistry & Molecular Biology
Zhibao Wang, Bo Cao, Peng Ji, Fan Yao
Summary: Propofol inhibits tubular structure formation and various biological functions of tumor-associated endothelial cells, including migration, adhesion, proliferation, and survival, by suppressing the expression and secretion of multiple pro-angiogenic factors and specific signaling pathways. These findings provide preclinical evidence for the anti-cancer properties of propofol and its potential mechanisms in inhibiting tumor growth and metastasis.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Valentina Di Nisio, Gianna Rossi, Alessandro Chiominto, Ezio Pompili, Sandra Cecconi
Summary: This study investigates the effects of aging and parity on VEGF-A/VEGFR protein content and signaling in mouse ovaries. The results show that the protein content of VEGF-A and phosphorylated VEGFR2 significantly decreases in post-reproductive (PM) ovaries, but remains unchanged in other groups. Additionally, the downstream signaling pathways and protein content of markers related to angiogenesis and cell cycle progression are modulated in an age- and parity-dependent manner.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Multidisciplinary
Subin Son, Chuangli Zhang, Miae Won, Paramesh Jangili, Minhyeok Choi, Jiasheng Wu, Jong Seung Kim
Summary: The study introduced a sunitinib-conjugated sonosensitizer to enhance anticancer efficacy by inhibiting VEGF-mediated antiangiogenesis and inducing cellular/tumor damage by ROS under ultrasound irradiation. The sonosensitizer showed good selectivity and cytotoxicity towards VEGFR-positive cells, providing an enhanced antitumor effect. This approach holds promise for optimizing anticancer performance by utilizing sonodynamic therapy in conjunction with antiangiogenics in various malignancies.
Article
Multidisciplinary Sciences
Yanxia Li, Nelusha Amaladas, Marguerita O'Mahony, Jason R. Manro, Ivan Inigo, Qi Li, Erik R. Rasmussen, Manisha Brahmachary, Thompson N. Doman, Gerald Hall, Michael Kalos, Ruslan Novosiadly, Oscar Puig, Bronislaw Pytowski, David A. Schaer
Summary: Combined blockade of VEGFR-2 and PD-1-axis pathways enhances anti-tumor efficacy by modulating immune cell infiltration and inducing immune activation. The immune activation signature resulting from combination therapy contributes to the enhanced anti-tumor activity.
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.
